story of the week
Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
Lancet Oncol 2024 Oct 29;[EPub Ahead of Print], PL Zinzani, K Izutsu, N Mehta-Shah, SK Barta, K Ishitsuka, R Córdoba, S Kusumoto, E Bachy, K Cwynarski, G Gritti, A Prica, E Jacobsen, T Feldman, Y Guillermin, D Ennishi, DH Yoon, ED Domenech, J Zain, J Wang, JS Kim, MV Poel, J Jin, S Wu, Y Chen, T Moriyama, A Inoue, K Nakajima, SM HorwitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.